BAP1-inactivated melanocytic tumor (BIMT) is a group of melanocytic neoplasms with epithelioid cell morphology molecularly characterized by the loss of function of BAP1, a tumor suppressor gene located on chromosome 3p21, and a mutually exclusive mitogenic driver mutation, more commonly BRAF. BIMTs can occur as a sporadic lesion or, less commonly, in the setting of an autosomal dominant cancer susceptibility syndrome caused by a BAP1 germline inactivating mutation. Owing to the frequent identification of remnants of a conventional nevus, BIMTs are currently classified within the group of combined melanocytic nevi. "Pure" lesions can also be observed. We studied 50 BIMTs from 36 patients. Most lesions were composed of epithelioid melanocytes of varying size and shapes, resulting extreme cytomorphological heterogeneity. Several distinctive morphological variants of multinucleated/giant cells were identified. Some hitherto underrecognized microscopic features, especially regarding nuclear characteristics included nuclear blebbing, nuclear budding, micronuclei, shadow nuclei, peculiar cytoplasmic projections (ant-bear cells) often containing micronuclei and cell-in-cell structures (entosis). In addition, there were mixed nests of conventional and BAP1-inactivated melanocytes and squeezed remnants of the original nevus. Of the 26 lesions studied, 24 yielded a BRAF mutation, while in the remaining two cases there was a RAF1 fusion. BAP1 biallelic and singe allele mutations were found in 4/22 and 16/24 neoplasms, respectively. In five patients, there was a BAP1 germline mutation. Six novel, previously unreported BAP1 mutations have been identified. BAP1 heterozygous loss was detected in 11/22 lesions. Fluorescence in situ hybridization for copy number changes revealed a related amplification of both RREB1 and MYC genes in one tumor, whereas the remaining 20 lesions studied were negative; no TERT-p mutation was found in 14 studied neoplasms. Tetraploidy was identified in 5/21 BIMTs. Of the 21 patients with available follow-up, only one child had a locoregional lymph node metastasis. Our results support a progression of BIMTs from a conventional BRAF mutated in which the original nevus is gradually replaced by epithelioid BAP1-inactivated melanocytes. Some features suggest more complex underlying pathophysiological events that need to be elucidated.

Bioptical Laboratory Pilsen Czech Republic

Department of Dermatology University Hospital of Zurich Zurich Switzerland

Department of Environmental Biological and Pharmaceutical Sciences and Technologies University of Campania Luigi Vanvitelli Caserta Italy

Department of Pathology Emergency Clinical County Hospital Pius Brinzeu Timisoara Romania

Department of Pathology Regional Hospital Hranice Czech Republic

Department of Pathology University Hospital Campus Bio Medico Rome Italy

Department of Plastic Reconstructive and Aesthetic Surgery Campus Bio Medico di Roma University Rome Italy

Institute of Pathology University of Ostrava Ostrava Czech Republic

Laboratory of Pathology CSD Health Care Ltd Kyiv Ukraine

New Cytology Laboratory Roma Italy

Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University of the Ministry of Healthcare Russian Federation Moscow Russia

Sikl's Department of Pathology Medical Faculty in Pilsen Charles University Prague Pilsen Czech Republic

Zobrazit více v PubMed

Elder, D. E., Massi, D., Scolyer, R. A., Willemze, R. & eds. WHO Classification of Skin Tumours. 4th edn. Lyon, France: International Agency for Research on Cancer (IARC) (2018).

Busam, K. J., Sung, J., Wiesner, T., von Deimling, A. & Jungbluth, A. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. Am. J. Surg. Pathol. 37, 193–199 (2013). PubMed DOI

Blokx, W. A. et al. NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report. Virchows Arch. 466, 117–121 (2015). PubMed DOI

Donati, M. et al. RAF1 gene fusions as a possible driver mechanism in rare BAP1-inactivated melanocytic tumors: a report of 2 cases. Am. J. Dermatopathol. 42, 961–966 (2020). PubMed DOI

Wiesner, T. et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am. J. Surg. Pathol. 36, 818–830 (2012). PubMed DOI PMC

Shain, A. H. et al. The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 373, 1926–1936 (2015). PubMed DOI

Garfield, E. M. et al. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors. J. Am. Acad. Dermatol. 79, 525–534 (2018). PubMed DOI

Wiesner, T. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018–1021 (2011). PubMed DOI PMC

Abdel-Rahman, M. H. et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856–859 (2011). PubMed DOI

Njauw, C. N. et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7, e35295 (2012). PubMed DOI PMC

Popova, T. et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet. 92, 974–980 (2013). PubMed DOI PMC

Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025 (2011). PubMed DOI PMC

Wiesner, T. et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J. Clin. Oncol. 30, e337–e340 (2012). PubMed DOI

Ardakani, N. M., Palmer, D. L. & Wood, B. A. BAP1 deficient malignant melanoma arising from the intradermal component of a congenital melanocytic naevus. Pathology 47, 707–710 (2015). PubMed DOI

Marušić, Z., Buljan, M. & Busam, K. J. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome. J. Cutan. Pathol. 42, 406–412 (2015). PubMed DOI

Gerami, P. et al. Multiple cutaneous melanomas and clinically atypical moles in a patient with a novel germline BAP1 mutation. JAMA Dermatol. 151, 1235–1239 (2015). PubMed DOI PMC

Aung, P. P. et al. Melanoma with loss of BAP1 expression in patients with no family history of bap1-associated cancer susceptibility syndrome: a case series. Am. J. Dermatopathol. 41, 167–179 (2019). PubMed DOI PMC

Carbone, M. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 10, 179 (2012). PubMed DOI PMC

Wysozan, T. R., Khelifa, S., Turchan, K. & Alomari, A. K. The morphologic spectrum of germline-mutated BAP1-inactivated melanocytic tumors includes lesions with conventional nevic melanocytes: a case report and review of literature. J. Cutan. Pathol. 46, 852–857 (2019). PubMed DOI

Louw, A. et al. Histologically diverse BAP1-deficient melanocytic tumors in a patient with BAP1 tumor predisposition syndrome. Am. J. Dermatopathol. 42, 872–875 (2020). PubMed DOI

Foretová, L. et al. BAP1 syndrome - predisposition to malignant mesothelioma, skin and uveal melanoma, renal and other cancers. Klin. Onkol. 32, 118–122 (2019). PubMed

Donati, M. et al. Spitz tumors with ROS1 fusions: a clinicopathological study of 6 cases, including FISH for chromosomal copy number alterations and mutation analysis using next-generation sequencing. Am. J. Dermatopathol. 42, 92–102 (2020). PubMed DOI

Šteiner, P., Pavelka, J., Vaneček, T., Miesbauerová, M. & Skálová, A. Molecular methods for detection of prognostic and predictive markers in diagnosis of adenoid cystic carcinoma of the salivary gland origin. Cesk. Patol. 54, 132–136 (2018). PubMed

Švajdler, M. et al. Fibro-osseous pseudotumor of digits and myositis ossificans show consistent COL1A1-USP6 rearrangement: a clinicopathological and genetic study of 27 cases. Hum. Pathol. 88, 39–47 (2019). PubMed DOI

Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). PubMed DOI PMC

Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018). PubMed DOI

Hilbers, M. L. et al. Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center. Oncotarget 12, 125–130 (2021). PubMed DOI PMC

Gerami, P. et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am. J. Surg. Pathol. 36, 808–817 (2012). PubMed DOI

Michal, M. Cellular blue naevi with microalveolar pattern-a type of naevus frequently confused with melanoma. Pathol. Res. Pract. 194, 83–86 (1998). PubMed DOI

Kazakov, D. V. & Michal, M. Melanocytic “ball-in-mitts” and “microalveolar structures” and their role in the development of cellular blue nevi. Ann. Diagn. Pathol. 11, 160–175 (2007). PubMed DOI

Piris, A., Mihm, M. C. Jr. & Hoang, M. P. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum. Pathol. 46, 239–245 (2015). PubMed DOI

Haugh, A. M. et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 153, 999–1006 (2017). PubMed DOI PMC

Yeh, I. et al. Ambiguous melanocytic tumors with loss of 3p21. Am. J. Surg. Pathol. 38, 1088–1095 (2014). PubMed DOI PMC

Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017). PubMed DOI

Bastian, B. C., LeBoit, P. E. & Pinkel, D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am. J. Pathol. 157, 967–972 (2000). PubMed DOI PMC

Sunshine, J. C. et al. Melanocytic neoplasms with MAP2K1 in frame deletions and spitz morphology. Am. J. Dermatopathol. 42, 923–931 (2020). PubMed DOI PMC

Donati, M. et al. MAP2K1-mutated melanocytic neoplasms with a SPARK-like morphology. Am. J. Dermatopathol. 43, 412–417 (2021). PubMed DOI

Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281–298 (2015). PubMed DOI

Llamas-Velasco, M., Pérez-Gónzalez, Y. C., Requena, L. & Kutzner, H. Histopathologic clues for the diagnosis of Wiesner nevus. J. Am. Acad. Dermatol. 70, 549–554 (2014). PubMed DOI

Webster, J. D. et al. The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma. Pigment Cell Melanoma Res. 32, 269–279 (2019). PubMed DOI

Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer. 95, 496–505 (2006). PubMed DOI PMC

Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005). PubMed DOI

Saggini, A. et al. Uncommon histopathological variants of malignant melanoma. Part 2. Am. J. Dermatopathol. 41, 321–342 (2019). PubMed DOI

Houlier, A. et al. Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations. Mod. Pathol. 33, 846–857 (2020). PubMed DOI

O’Shea, S. J. et al. Histopathology of melanocytic lesions in a family with an inherited BAP1 mutation. J. Cutan. Pathol. 43, 287–289 (2016). PubMed DOI

Pouryazdanparast, P., Haghighat, Z., Beilfuss, B. A., Guitart, J. & Gerami, P. Melanocytic nevi with an atypical epithelioid cell component: clinical, histopathologic, and fluorescence in situ hybridization findings. Am. J. Surg. Pathol. 35, 1405–1412 (2011). PubMed DOI

Ye, J., Sheahon, K. M., LeBoit, P. E., McCalmont, T. H. & Lang, U. E. BAP1-inactivated melanocytic tumors demonstrate prominent centrosome amplification and associated loss of primary cilia. J. Cutan. Pathol. 8, 1353–1360 (2021). DOI

Borel, F., Lohez, O. D., Lacroix, F. B. & Margolis, R. L. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc. Natl. Acad. Sci. USA 99, 9819–9824 (2002). PubMed DOI PMC

Fischer, A. S. & High, W. A. The difficulty in interpreting gene expression profiling in BAP-negative melanocytic tumors. J. Cutan. Pathol. 45, 659–666 (2018). DOI

Gammon, B., Traczyk, T. N. & Gerami, P. Clumped perinuclear BAP1 expression is a frequent finding in sporadic epithelioid Spitz tumors. J. Cutan. Pathol. 40, 538–542 (2013). PubMed DOI

Hühns, M. et al. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Mod. Pathol. 33, 1220–1231 (2019). PubMed DOI

Lee, S. et al. TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms. Sci. Rep. 5, 11200 (2015). PubMed DOI PMC

Cohen, J. N., Yeh, I., Mully, T. W., LeBoit, P. E. & McCalmont, T. H. Genomic and clinicopathologic characteristics of PRKAR1A-inactivated melanomas: toward genetic distinctions of animal-type melanoma/pigment synthesizing melanoma. Am. J. Surg. Pathol. 44, 805–816 (2020). PubMed DOI

Yeh, I. New and evolving concepts of melanocytic nevi and melanocytomas. Mod. Pathol. 33, 1–14 (2020). PubMed DOI